300results about How to "High antibody titer" patented technology

A chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid (HBc) protein is disclosed that contains an immunogen for inducing the production of antibodies to the influenza M2 protein. An immunogenic influenza sequence in two to four copies is preferably expressed at or near the N-terminus or in the HBc immunogenic loop sequence. The HBc chimer preferably contains an influenza-specific T cell epitope and is preferably engineered for both enhanced stability of self-assembled particles and enhanced yield of those chimeric particles. Methods of making and using the chimers are also disclosed.

The invention discloses a tilapia streptococcus agalactiae IgM antibody capture ELISA detection kit. An anti-tilapia IgM specific monoclonal antibody is secreted from an anti-tilapia IgM hybridoma cell strain 2H5/B5 assigned the accession number CCTCC No:C201277. The kit includes an ELISA plate which is coated by the monoclonal antibody, an antigen tilapia streptococcus agalactiae SIP fusion protein, an IgG-HRP enzyme marker of an SIP fusion protein rabbit polyclonal antibody, an antibody diluent, a washing solution, a coloring reagent, a stop solution, a positive control and a negative control. The anti-tilapia IgM specific monoclonal antibody is high in titer and specificity. The kit is simple in operation, is high in sensitivity, is strong in specificity, can be used in detection of a tilapia streptococcus agalactiae IgM antibody and has a quite high application value.

The invention relates to a hybridoma cell strain 7G11 and an antibody thereof. The hybridoma cell strain 7G11 is delivered to the China Center for Type Culture Collection for collection on December 27, 2016, with the collection number of CCTCC NO: C201703. The hybridoma cell strain 7G11 can generate a monoclonal antibody capable of resisting streptospora acid, can specifically detect the streptospora acid and has important significance for detection of the streptospora acid.

The invention provides a preparation method of an aluminium adjuvant. The method comprises the step that water solution of aluminium salt and/or phosphate is contacted with water solution of sodium hydroxide and/or ammonia, and is characterized in that the pH value is constant during the whole process that the water solution of aluminium salt and/or phosphate is contacted with the water solution of sodium hydroxide and/or ammonia. The invention further provides an aluminium adjuvant obtained through the preparation method and the application of the aluminium adjuvant on vaccine. The preparation method of aluminium adjuvant has the advantage that the obtained product is uniform in structure, stable in property and reliable in quality; and the aluminium adjuvant prepared through the method can adsorb more vaccine.

The invention relates to a compound immunoenhancement agent and an application thereof on preparing a vaccine for birds. The compound immunoenhancement agent contains 5ng-10mg/mL of poly IC, 10ng-10mg/mL of muramyl dipeptide, 10ng-5mg/mL of levamisole, 10ng-5mg/mL of resiquimod and 10ng-5mg/mL of imiquimod. After the immunoenhancement agent and H5 hypotype bird flu inactivated vaccine are mixed together, antibody can be produced one week earlier, and the antibody titer is improved above 1.8log2. After chicken are immunized through H5 hypotype bird flu inactivated vaccine, H9 hypotype bird flu vaccine or infectious bronchitis vaccine which contains the compound vaccine immunoenhancement agent, the window phases of the antibody production are shortened, the antibody titer of the vaccine is improved, the immunization duration is prolonged, and the probability of infection disease is reduced.

A preparation method of a purified vitelline freezing antibody for chickens infectious bursal disease is characterized in that: high purity antigens are adopted to vaccinate IBDV B87 to SPF chickens, then velvet urine, idiosome, velvet urine membrence are acquired, grinded, filtered and inactivated to antigens, and the steps are: producing immune eggs, collecting high immune egg, separating vitelline, diluting with distilled water, inactivating, extraction, decentering, inactivating, freezing and checking; the eggs is radiated by Co60 to kill viruses and bacterium, and finally froze by novel immuno-enhancer - Astragali Polysaccharoses and preserved under a temperature of 2-8 DEG C. Composite drugs for prevention and therapy are prepared by adopting the vitelline antibody for chickens infectious bursal disease as major components and cooperating with a novel immuno-enhancer, to decrease the jeopardy of the chicken breeding industry, and improve the living level of people and benefit mankind.

The invention relates to the technical field of biomedicine, and particularly provides a fusion protein of an SVV and an FMDV, an encoding gene of the fusion protein, an expression vector, a cell line, engineering bacteria, a vaccine and application. The fusion protein is obtained by replacing an epitope capable of inducing the body to produce a neutralizing antibody with a decoy epitope and comprises SVV VP1 protein fragments, FMDV VP1 protein fragments and complement C3d protein fragments. The fusion protein combines antigens for inducing the body to produce the neutralizing antibody, of twopathogens of SVV and FMDV, and the safety of the antigens is improved while the antigenic epitopes of the SVV and the FMDV are reserved. The complement C3d molecules can excite nonspecific body fluidand cellular immune reactions in the body, and play an important role in increasing the antibody titer of the vaccine, and activating the cellular immune response of the body. The vaccine prepared bymeans of the fusion protein is safe and effective, and hydroa and foot-and-mouth diseases can be effectively prevented.

The invention relates to a conjugate of monophosphate A (MPLA) and carbohydrate antigen Globo H and capable of serving as an antitumor vaccine and a preparation method and application thereof. The conjugate can be prepared through a chemical method and has the advantages of definite structure, clear composition and adjuvant needlessness. In addition, the invention further provides the applicationof the conjugate in preparing drug for treating or preventing cancer.

The invention discloses recombinant porcine reproductive and respiratory syndrome virus (PRRSV) virus-like particles (VLP) and a preparation method and an application thereof. Based on comparative analysis of GP5 of a PRRSV epidemic strain and an M gene sequence, a GP5 and M tandem sequence GP5M is synthesized artificially, the synthesized GP5M gene sequence is cloned into a vector with a pBAC5 plasmid as a skeleton, the baculovirus transfer vector pBAC-PRRSVGP5M is obtained, the recombinant bacmid rBacmid-GP5M is obtained, sf9 cells are transfected with the bacmid, and the recombinant baculovirus Ac-PRRSVGP5M is obtained. The PRRSV GP5 and M protein are expressed efficiently by the recombinant baculovirus, and the virus-like particles are formed. A subunit vaccine prepared by the proteinexpressed by the recombinant baculovirus can induce a body to produce a specific immune response after immunizing animals and can protect the pig body against the strong poison attacking of porcine reproductive and respiratory syndrome virus.

The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides composition comprising a virus-like particle (VLP) linked to at least one antigen, wherein said antigen is NGF antigen. The invention also provides a process for producing the composition. The compositions of this invention are useful in the production of vaccines, in particular, for the treatment of pain. Moreover, the compositions of the invention induce efficient immune responses, in particular antibody responses.

The present invention relates to an avian influenza H9 subtype inactivated vaccine, which is formed by mixing two strains of inactivated H9 subtype avian influenza viruses and an oil adjuvant, wherein the two strains of the inactivated H9 subtype avian influenza viruses are respectively the HZ strain and the FJ strain, the HA gene sequence of the HZ strain is represented by SEQ ID NO:1, and the HA gene sequence of the FJ strain is represented by SEQ ID NO:2. According to the preparation method, the virus solution of the HZ strain and the virus solution of the FJ strain of the H9 subtype avian influenza viruses are prepared and inactivated, the oil phase solution and the water phase solution are prepared, and emulsification is performed to obtain the finished product. According to the present invention, the two strains of the H9 subtype avian influenza viruses separated from different places are utilized to prepare the inactivated vaccine with characteristics of strong immunogenicity and good cross-protection property, wherein the inactivated vaccine can be used for prevention of chicken H9 subtype avian influenza diseases. In addition, after the inactivated vaccine is adopted to immunize chicken, the antibody titer is high so as to make the chicken have good virus challenge protection property on the H9 subtype strains epidemic in different places, the safety is high, and the efficacy is stable.

The present invention provides methods of vaccination as well as pharmaceutical combinations and kits for enhancing vaccine effectiveness, including for immunodeficient or immunecompromised patients, including non-responders and low-responders to vaccination. As disclosed herein, the invention relates to administering a vaccine and a regimen of thymosin alpha peptide so as to provide higher antibody titers, speed the development of such antibody titers, and/or to provide for a longer duration of such antibody titers, thereby providing a greater protective effect. In another aspect, the invention allows for reducing a vaccine dose, such as an influenza vaccine dose, by administration of a thymosin peptide regimen.

The invention discloses a preparation and freeze-dried storage method of pseudorabies standard positive serum. The preparation comprises the following steps: immunizing a rabbit twice with an inactivated PRV (pseudorabies virus) solution, then, immunizing the rabbit once with the inactivated PRV solution, and collecting the serum; adding a protective agent sodium chloride, trehalose, monosodium glutamate and L-arginine into the serum, fully dissolving, filtering to remove bacteria, and subpackaging; adding the subpackaged serum into a freeze dryer box, and performing freeze-drying according to a freeze-drying curve shown as fig.1 described in the specification to obtain the pseudorabies standard positive serum. For the pseudorabies standard positive serum obtained by the method disclosed by the invention, PRV neutralizing antibody titer is more than 1:512, the antibody titer remains unchanged after the pseudorabies standard positive serum is stored for 60 months at 2-8 DEG C, so that the pseudorabies standard positive serum has good stability, can fully neutralize pseudorabies virus in vaccine exogenous virus and specificity detection, and provides a good technical support for quality inspection of pseudorabies virus vaccines.

The invention discloses a composition for resisting swine foot-and-mouth disease, freeze-dried powder, and a preparation method and use of the freeze-dried powder, and belongs to the technical field of veterinary feed additives. The composition comprises, by weight, 95-100 parts of a swine foot-and-mouth disease-resistant yolk antibody and 1-5 parts of a swine foot-and-mouth disease-resistant transfer factor. The freeze-dried powder comprises, by weight, 95-97 parts of the swine foot-and-mouth disease-resistant yolk antibody, 1-2 parts of the swine foot-and-mouth disease-resistant transfer factor, 0.2-0.3 parts of an inactivator, 0.01-0.02 parts of an antiseptic and 2.05-3.6 parts of a heat-resistant freeze-dried protective agent, and has the advantages of low preservation conditions, long preservation time, high antibody titer and good biological activity. Through combined use of the swine foot-and-mouth disease-resistant yolk antibody and the swine foot-and-mouth disease-resistant transfer factor, the freeze-dried powder has effects of preventing and treating swine foot-and-mouth disease, improves swine immunity and survival rate, is convenient for use and has a low cost.

The invention provides an infectious bursal disease virus Vero cell-adapted strain and belongs to the field of bioengineering. The related infectious bursal disease virus Vero cell-adapted strain is named Ck /Jiangsu/ NJ-23/2008 and has a collection No. of CGMCCNO.8852. The infectious bursal disease virus Vero cell-adapted strain which can efficiently multiply on serum-free cultured Vero cell is finally obtained through wild strain separation, chick embryo passage, Vero cell passage adaption; the infectious bursal disease virus Vero cell-adapted strain is subjected to continuous passage culture on the serum-free cultured Vero cell and TCID50 can be kept to be higher than 108.5/mL. Virus culture solution is inactivated and prepared into oil emulsion; after the prepared oil emulsion is used to immunize chicken, detection proves that the prepared oil emulsion has good immunogenicity. The infectious bursal disease virus (IBDV) strain and the production process thereof are simple, safe and efficient and suitable for industrial culture.

The invention discloses a preparation method of highly pathogenic H7N9 avian influenza virus, and the method can improve immunogenicity of virus. The preparation method comprises the following steps:preparing a Q226L mutated HA gene: preparing the gene sequence of full-length HA protein of Q226L-mutated highly pathogenic H7N9 avian influenza virus to obtain the Q226L mutated HA gene; rescuing thevirus: adopting the Q226L mutated HA gene to rescue the recombinant influenza virus. The invention further discloses the highly pathogenic H7N9 avian influenza virus prepared by the method, a vaccineprepared by using the highly pathogenic H7N9 avian influenza virus and a preparation method of the vaccine, and a detection reagent prepared by using the highly pathogenic H7N9 avian influenza virus.The preparation method of the highly pathogenic H7N9 avian influenza virus improves the biosecurity of the recombinant virus and immunogenicity.

The invention relates to a bath or oral application of immune activate compound in the fish immunity, wherein the invention has the advantages that: said compound ISCOMs is used to bath immunity to improve the antibody level and improve the increment transformation ability of T-lymphocyte, to induce the immune protection; when in the same dosage, the antibody level is higher than non-adjuvant group and the ISM1312 group; and the ISCOMs used in oral can improve the antibody level and improve the increment transformation ability of T-lymphocyte, to induce the immune protection.

The invention discloses a preparation method of chimeric vaccine by using Ii-Key active tetrapeptide carrying Fabricius bursa VP2 and newcastle disease HN antigen peptide epitope, which is characterized in that the chimera gene of Ii-Key and chicken infectious Fabricius bursa VP2 peptide epitope (197-209) and newcastle disease HN antigen peptide epitope (345-353) is artificially synthesized, a pET-32a prokaryotic expression vector is respectively inserted, then escherichia coli Rosetta is conversed, and chimera gene is purified through a nickel affinity column chromatography, an enzyme-linked immunosordent assay(ELISA) is employed for detecting antibody level in mice with recombinant protein immunization SPF grade BALb/c; and vaccine is compared with a simple VP2197-209/HN345-353 series epitope control group. The antibody titer of the chimeric vaccine group based on active Ii-Key is increased by 13.72 times on average. The chimeric vaccine has the characteristics of strong specialty, easy preparation and good immunization effect.